Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
8.29
+0.30 (3.75%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Market Cap
Fulcrum Therapeutics has a market cap or net worth of $552.12 million as of April 17, 2026. Its market cap has increased by 261.42% in one year.
Market Cap
552.12M
Enterprise Value
206.25M
1-Year Change
261.42%
Ranking
Category
Stock Price
$8.29
Market Cap Chart
Since July 18, 2019, Fulcrum Therapeutics's market cap has increased from $301.64M to $552.12M, an increase of 83.04%. That is a compound annual growth rate of 9.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 17, 2026 | 552.12M | -26.00% |
| Dec 31, 2025 | 746.12M | 194.32% |
| Dec 31, 2024 | 253.51M | -39.25% |
| Dec 29, 2023 | 417.30M | 10.13% |
| Dec 30, 2022 | 378.93M | -47.15% |
| Dec 31, 2021 | 716.95M | 124.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jul 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Aclaris Therapeutics | 549.03M |
| Adlai Nortye | 548.80M |
| Shattuck Labs | 547.21M |
| Lyell Immunopharma | 544.72M |
| Verastem | 543.75M |
| Upstream Bio | 540.39M |
| AgomAb Therapeutics NV | 539.52M |
| enGene Therapeutics | 535.25M |